A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME.

Trial Profile

A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2015

At a glance

  • Drugs Tasadenoturev (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01582516).
    • 22 Apr 2012 Additional lead trial centres and investigator identified as reported by ClinicalTrials.gov.
    • 22 Apr 2012 Planned End Date changed from 28 Jul 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top